Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults

Cancer

Volumn 118, Issue 11, 2012, Pages 2925-2934

  MacK, Christina D ^a   Carpenter, William ^a,b   Meyer, Anne Marie ^b   Sanoff, Hanna ^c   Stürmer, Til ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

aged; colon cancer; colonic neoplasms mortality; colonic neoplasms therapy; comparative effectiveness research; health care disparities; oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AFRICAN AMERICAN; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; COLON SURGERY; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SEX DIFFERENCE;

AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; HEALTHCARE DISPARITIES; HUMANS; MALE; MEDICARE; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84861338289     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26622     Document Type: Article

References (54)

1. Altekruse S, Kosary C, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. Posted to the SEER web site, 2010, based on November 2009 SEER data submission. Available at: Accessed on March 20, 2010.
2. American Cancer Society. Cancer Facts and Figures 2011-2013. Atlanta, GA: American Cancer Society; 2011. Available at: Accessed April 2, 2011.
3. Ries LA, Kosary CL, Hankey BF, Miller BA, Edwards BK,. SEER cancer statistics review, 1973-1995. Bethesda, MD: National Cancer Institute; 1998.
4. Irby K, Anderson WF, Henson DE, Devesa SS,. Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev. 2006; 15: 792-797.
5. Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC: National Academies Press; 2003.
6. Institute of Medicine. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: National Academies Press; 1999.
7. Bach PB, Cramer LD, Warren JL, Begg CB,. Racial differences in the treatment of early stage lung cancer. N Engl J Med. 1999; 341: 1198-1205.
8. Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005; 35: 88-95.
9. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B,. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13: 93-100.
10. Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J,. Racial differences in screening for prostate cancer in the elderly. Arch Intern Med. 2004; 164: 1858-1864.
11. Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR,. Race and trust in the health care system. Public Health Rep. 2003; 118: 358-365.
12. Halbert CH, Armstrong K, Gandy OH Jr, Shaker L,. Racial differences in trust in health care providers. Arch Intern Med. 2006; 166: 896-901.
13. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
14. Govindarajan R, Shah RV, Erkman LG, et al. Racial differences in the outcome of patients with colorectal carcinoma. Cancer. 2003; 97: 493-498.
15. Haas JS, Brawarsky P, Iyer A, Fitzmaurice GM, Neville BA, Earle C,. Association of area sociodemographic characteristics and capacity for treatment with disparities in colorectal cancer care and mortality. Cancer. 2011; 117: 4267-4276.
16. Morris AM, Billingsley KG, Hayanga AJ, Matthews B, Baldwin LM, Birkmeyer JD,. Residual treatment disparities after oncology referral for rectal cancer. J Natl Cancer Inst. 2008; 100: 738-744.
17. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 1192-1202.
18. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43-47.
19. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL,. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99: 1290-1295.
20. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001; 1: 65-70.
21. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM,. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009; 27: 4109-4115.
22. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94: 1160-1167.
23. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23: 8671-8678.
24. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
25. National Cancer Institute. Highlights from ASCO 2003. May 31, 2003. Available at: Accessed October 30, 2010.
26. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
27. Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program [review]. Cancer. 2010; 116: 4440-4449.
28. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-18.
29. National Cancer Institute. SEER-Medicare: Brief Description of the SEER-Medicare Database. Available at: Accessed September 22, 2010.
30. American Society of Clinical Oncology and National Comprehensive Cancer Network, Inc. ASCO/NCCN Quality Measures: Breast and Colorectal Cancers. April 2007 update. Available at: Accessed Mar 20, 2010.
31. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL,. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002; 40 (8 suppl): IV-19-25.
32. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. December 17, 2010. Available at: Accessed June 26, 2011.
33. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D,. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
34. Li R, Chambless L,. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007; 17: 227-236.
35. Greenland S, Lash TL, Rothman KJ,. Concepts of interaction. In:, Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 71-78.
36. Vandenbroucke JP, von EE, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4: e297.
37. Glymour MM, Greenland S,. Causal diagrams. In:, Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 183-194.
38. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Weeks JC, Kahn KL, Scymura MJ, Schrag D,. Effectiveness of oxaliplatin containing adjuvant chemotherapy for stage III colon cancer. JNCI. (in press).
39. American Cancer Society. Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010. Available at: Accessed April 2, 2011.
40. Roetzheim RG, Pal N, Gonzalez EC, et al. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000; 90: 1746-1754.
41. Baldwin LM, Dobie SA, Billingsly K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97: 1211-1220.
42. Dominitz JA, Samsa GP, Landsman P, Provenzale D,. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998; 82: 2312-2320.
43. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
44. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-3116.
45. Frost DW, Cook DJ, Heyland DK, Fowler RA,. Patient and healthcare professional factors influencing end-of-life decision-making during critical illness: a systematic review. Crit Care Med. 2011; 39: 1174-1189.
46. Kwak J, Haley WE,. Current research findings on end-of-life decision making among racially or ethnically diverse groups [review]. Gerontologist. 2005; 45: 634-641.
47. Sturmer T, Rothman KJ, Avorn J, Glynn RJ,. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol. 2010; 172: 843-854.
48. Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996; 124: 577-584.
49. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3-18.
50. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL,. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002; 40 (8 suppl): IV-19-25.
51. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL,. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40: IV-43-48.
52. Kind S, Virnig B,. The use of Medicare claims data for ascertainment of cancer diagnosis dates [abstract]. Abstr Acad Health Serv Res Health Policy Meet. 2001; 18: 23.
53. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-55-61.
54. Carpenter WR, Reeder-Hayes K, Bainbridge J, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care. 2011; 49: 172-179.